Our Management Team
Chief Executive Officer & Board Director
David Elliot has more than 25 years of medical device and biotech experience in sales and marketing leadership, product and market development, strategic planning, business development and program management. He has held CEO, President, COO and Vice President positions at a range of publicly-traded, private and start-up medical device companies including ACell (now Integra), St. Jude Medical (now Abbott Medical) TYRX, Inc. (now Medtronic), Valam, VistaCare (now Odyssey/Gentiva), VasClip, Advanced Respiratory (now Hillrom), Guidant (now Boston Scientific), and Eli Lilly.
His experience includes establishing Strategic direction, M&A and building and leading high-performing sales and marketing teams that drive revenue growth and build enterprise value. Mr. Elliot earned a Bachelor of Arts in English from Connecticut College and an MBA with concentrations in Marketing and Finance from the University of Chicago Booth School of Business.
David Humbert, RAC
Vice President of Regulatory and Clinical Affairs
David Humbert has over thirty years of advanced medical device regulatory experience, including managing successful approval applications for both active implantable devices like the WorldHeart left ventricular assist system, and minimally-invasive devices similar to Zelegent’s novel device. He co-managed the pivotal, multi-center clinical study for Zelegent, Inc., and authored both of the Premarket Notification submissions for the Elevo® Set, which were cleared by FDA in 2018 and 2022.
Mr. Humbert’s career has included directing the regulatory efforts at Emphasys Medical and Arstasis, Inc. from 2007-2009, and supporting several Class III medical device submission projects for Oxford International and Black Diamond Networks from 2009-2014. He was Director of Regulatory Affairs at WorldHeart, Inc. from 2001-2007, a Corporate Consultant to the Regulatory Affairs group at Boston Scientific from 1997-2001, and supported the broad regulatory affairs function at Guidant Corporation’s Devices for Vascular Intervention, Inc. from 1990-1994. He was one of the first 500 regulatory professionals in the U.S. to earn the Regulatory Affairs Certified (RAC) credential in 1993, and has been designated RAC Emeritus by the Regulatory Affairs Professional Society.
Director of Engineering
Rick Lilly brings 19 years of medical device engineering experience to Zelegent, with a career that has focused on bio-resorbable, implantable medical devices, like the Elevo™ implant. Prior to Zelegent, Mr. Lilly spent three years as the Director of R&D for Articulinx, Inc., a company developing a small joint flexibility implant. Prior to Articulinx, he spent four years as the R&D Engineering Manager for Transcend Medical, Inc., in which he brought the inserter for the company’s ophthalmology device from concept to clinic in just four months. Prior to Transcend, he was the R&D Program Manager at Apneon, Inc., a company developing a complex implantable anti-snoring device, where he took over for Joseph Paraschac. He similarly succeeds Mr. Paraschac at Zelegent, who was the engineer who refined the Elevo™ implant design before him, and one of the most prolific inventors in the field of sleep apnea and suture handling.
Mr. Lilly is a named inventor on 11 issued medical device U.S. patents, including sutureless vessel plugs and ocular implantables, and holds a BSME degree from California Polytechnic State University.